Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients

Jing Wang; Min Zhou; Qi-Guo Zhang; Jingyan Xu; Tong Lin; Rong-Fu Zhou; Juan Li; Yong-Gong Yang; Bing Chen; Jian Ouyang

doi:10.18632/oncotarget.14182

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients

Jing Wang, Min Zhou, Qi-Guo Zhang, Jingyan Xu, Tong Lin, Rong-Fu Zhou, Juan Li, Yong-Gong Yang, Bing Chen and Jian Ouyang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:9708-9716. https://doi.org/10.18632/oncotarget.14182

Metrics: PDF 1611 views | HTML 1877 views | ?

Abstract

Jing Wang1,*, Min Zhou1,*, Qi-Guo Zhang1,*, Jingyan Xu1,*, Tong Lin1, Rong-Fu Zhou1, Juan Li1, Yong-Gong Yang1, Bing Chen1, Jian Ouyang1

1Department of Hematology, The Affiliated DrumTower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, PR China

*These authors contributed equally to this work and should be considered as co-first authors

Correspondence to:

Jian Ouyang, email: [email protected]

Bing Chen, email: [email protected]

Keywords: diffuse large B-cell lymphoma, p65, NF-κB, international prognostic index

Received: July 25, 2016 Accepted: November 22, 2016 Published: December 26, 2016

ABSTRACT

Purpose: We estimated the expression of nuclear factor kappa B/p65 in non-germinal center B-cell-like subtype diffuse large B-cell lymphoma, to investigate its relationship to clinicopathological features, and to further evaluate its prognostic value and clarify its impact on survival.

Results: Among the 49 patients enrolled in this study, 14 (28.6%) had positive p65 expression. The negative p65 group had significantly better survival compared to the positive p65 group in terms of both the 3-year estimated OS (91.2% vs. 39.3%, p = 0.003) and PFS (75.6% vs. 26.5%, p = 0.002). In patients with 4 or more risk factors, p65 was an independent prognostic factor of OS (HR 5.99, 95%CI=1.39-25.75, p=0.016) and PFS (HR 4.01, 95%CI=1.15-14.00, p=0.029).

Materials and Methods: The expression of the NF-κB/p65 protein was deteremined by immunohistochemistry in 49 non-GCB DLBCL. Survival was assessed by the Kaplan–Meier method and Cox multivariate analysis. The median patient follow-up period was 24 months.

Conclusions: The expression of NF-κB/p65 has prognostic value in high risk non-GCB DLBCL, and it is a suitable target for the development of new therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14182

Publication Alerts

Research Papers:

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients

Abstract